ICR welcomes approval of immunotherapy for head and neck cancer in Scotland but warns of ‘home nations lottery’ 07 Sep 2020 The ICR has welcomed the approval by the Scottish Medicines Consortium (SMC) of the immunotherapy, pembrolizumab, as a first-line NHS treatment for some patients with head and neck cancer. Find out more Show/Hide
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020 The ICR has criticised the decision by NICE not to recommend the immunotherapy, pembrolizumab, as a first-line treatment for patients with advanced head and neck cancer and is calling for an urgent reassessment of the evidence for the drug’s benefit. Find out more Show/Hide
Major trial backs immunotherapy as standard first-line treatment for head and neck cancer 23 Nov 2019 Immunotherapy is better than standard ‘extreme’ chemotherapy as first-line treatment for advanced head and neck cancer and can keep some patients alive for more than three years, a major new trial reports. Find out more Show/Hide
ICR and The Royal Marsden form part of new radiotherapy research network after receiving major new funding 04 Nov 2019
ASCO 2019: Immunotherapy better than aggressive chemotherapy as first treatment option for recurrent head and neck cancer 04 Jun 2019
Immunotherapy keeps some patients with advanced head and neck cancer alive for more than three years 30 Nov 2018
ESMO 2018: Immunotherapy effective as first-line treatment for advanced head and neck cancer 22 Oct 2018
Viral gene therapy could improve results from breast reconstruction surgery after cancer treatment 24 Jan 2018